Guggenheim Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS) had its price target boosted by Guggenheim from $224.00 to $284.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 18th. Bank of America upped their price target on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, HC Wainwright restated a “buy” rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $326.25.

Krystal Biotech Trading Up 2.1%

Shares of KRYS stock opened at $272.50 on Wednesday. The firm has a market capitalization of $7.97 billion, a P/E ratio of 39.78 and a beta of 0.49. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $298.30. The firm’s fifty day simple moving average is $267.44 and its 200 day simple moving average is $212.98.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Equities research analysts anticipate that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity

In other news, Director Dino A. Rossi sold 18,950 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the completion of the transaction, the director directly owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. This represents a 19.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 56,450 shares of company stock worth $13,859,470. Company insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hantz Financial Services Inc. grew its holdings in shares of Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after purchasing an additional 179 shares during the last quarter. Bessemer Group Inc. boosted its position in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in Krystal Biotech in the third quarter valued at about $30,000. Salomon & Ludwin LLC bought a new stake in Krystal Biotech during the third quarter worth about $33,000. Finally, First Horizon Advisors Inc. grew its stake in Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.